Bayer Stock: Analyst Optimism Clashes with Technical Reality as Shares Trade Near Key Support

Bayer shares drop to €34.50, below key moving averages, as CEO rules out Monsanto spin-off. Analysts still target €49.47, but glyphosate litigation keeps stock volatile.

Bayer’s shares have fallen nearly 9% in the past week, landing at €34.50 — more than 30% below their February high of €49.93. Yet analysts still see the stock rising over 40% from current levels, with a consensus price target of €49.47. The yawning gap between technical deterioration and fundamental optimism sums up the tension gripping the German conglomerate.

CEO Bill Anderson has poured cold water on hopes of a quick value unlock through a Monsanto spin-off. He told investors that resolving the glyphosate litigation must come first before any structural changes are considered. The stance disappointed activists like Jeffrey Ubben and removed a near-term catalyst that many had counted on for share price recovery.

Technically, the chart is now flashing clear warning signals. The stock closed below its 200-day moving average of €35.73 on Wednesday, a level that flips from support to resistance. It also sits 10.4% under the 50-day average of €38.50 and 15% below the 100-day line at €40.65. The 14-day relative strength index has fallen to 32.6, approaching oversold territory but not yet confirming a reversal. With annualized 30-day volatility at 36.66%, price moves around these key levels are likely to be erratic in the short term.

On the operating side, Bayer reaffirmed its currency-adjusted guidance for 2026 and announced a clinical collaboration with Olema Oncology to test a combination of its drug Darolutamide for metastatic prostate cancer. To date, these developments have done little to arrest the slide. The market remains focused on the technical weakness.

A handful of analysts still see a buying opportunity. Bank of America maintained its buy recommendation this week, citing progress in the Roundup class-action lawsuits. mwb Research echoed the view that legal risks are already priced into the stock. The average analyst price target of €49.47 implies significant upside — but the market’s skepticism is reflected in the share price’s failure to respond to bullish calls.

The immediate technical focus is on whether Bayer can reclaim the 200-day moving average. A decisive move back above €35.73 could trigger a short-covering rally, while failure to do so would keep the bears in control. The next resistance to watch would be the 50-day average near €38.50.

The ultimate catalyst for the shares remains the U.S. glyphosate litigation. Until a verdict or settlement emerges, the stock is likely to remain volatile and range-bound. As one analyst put it, the gap between the price target and current reality reflects the immense uncertainty hanging over Bayer’s legal overhang.